However, while a CSF-1R blocking antibody is clinically useful in tenosynovial giant cell tumors driven by constitutive synovial CSF-1 production, clinical trials of CSF-1R inhibitors as single agents have proven disappointing (118, 122). Here, CSF1R is linked to giant cell tumor.